<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20091201002801N6</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-07-23</date_registration>
      <primary_sponsor>Vice chancellor for research, Mazandaran University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of Ventolin nebulizer with supportive treatment in Transient tachypnea of the newborns (TTN) admitted to the neonatal intensive care unit (NICU) of Imam Khomeini and Bouali Sari hospitals of Sari</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of Ventolin nebulizer with supportive treatment in Transient tachypnea of the newborns (TTN) admitted to the neonatal intensive care unit (NICU) of Imam Khomeini and Bouali Sari hospitals of Sari</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-07-01</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/71387</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Allocation of patients into two treatment groups will be by Stratified Permuted Block Randomization method with blocks of 4. First the patients are divided into two groups based on the severity of TTN, then in each group, using Block Randomization, the patients will receive one of the interventions. To generate random allocation, the sealed envelope site was used, which created the a random table with the code 105487821465911 for us, which shows how patients enter the two intervention groups, Blinding description: The nurse and the study participants do not know who is in which group. Placebo and drug have the same color and shape in appearance and are coded by the researcher and each patient will be given a drug code. Then the mediation is given to the nurse and nebulized.</study_design>
      <phase>3</phase>
      <hc_freetext>Transient tachypnea of newborn.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: In the intervention group, 0.1 mL of salbutamol (Ventolin, salbutamol sulfate 5 mg/mL) is nebulized in 3 mL of 0.9% normal saline. The standard dose of salbutamol is 0.15 mg/kg/dose. It will be nebulized every day with a jet-type nebulizer with a continuous oxygen flow of 5 liters per minute during a 10-minute period and every 6 hours for a day. Intervention 2: Control group: In the control group, they will receive 2 mL of 0.9% saline as a nebulizer.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Contact Dr. Roya Farhadi

When:
Informations will send within few days after the email.

To whom:
People working in academic institutions

Conditions:
Contact Dr. Roya Farhadi

Where to obtain:
Email

How to obtain:
Informations will send within few days after the email.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Maedeh Gouran</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>ساری بلوار پاسداران بیمارستان بوعلی، مرکز تحقیقات عفونی اطفال</address>
        <city>ساری</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4815838477</zip>
        <telephone>+98 11 3334 2334</telephone>
        <email>maedeh.gooran@gmail.com</email>
        <affiliation>Mazandaran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Roya Farhadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Booali hospital. Pasdaran Blvd</address>
        <city>Sari</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4815838477</zip>
        <telephone>+98 11 3334 3018</telephone>
        <email>rfarhadi@mazums.ac.ir</email>
        <affiliation>Mazandaran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Neonates with gestational age more than 34 weeks
Tachypnea with or without cyanosis
Respiratory distress
Chest X-ray findings in favor of TTN</inclusion_criteria>
      <agemin>1 year</agemin>
      <agemax>30 days</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Meconium aspiration
Other diseases in the radiography such as pneumonia and...
Complex Coronary heart disease (CHD)
Tachycardia above 180
Silverman Anderson score less than 46
Ventilator therapy since birth
Diagnosis of RDS during hospitalization
Administration of surfactant with diagnosis of RDS</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>P22.1</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Transient tachypnea of newborn</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: In the intervention group, 0.1 mL of salbutamol (Ventolin, salbutamol sulfate 5 mg/mL) is nebulized in 3 mL of 0.9% normal saline. The standard dose of salbutamol is 0.15 mg/kg/dose. It will be nebulized every day with a jet-type nebulizer with a continuous oxygen flow of 5 liters per minute during a 10-minute period and every 6 hours for a day</i_keyword>
      <i_keyword>Control group: In the control group, they will receive 2 mL of 0.9% saline as a nebulizer.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Primary CPAP (continuous positive airway pressure) duration. Timepoint: Time interval from start to end of CPAP. Method of measurement: Minute and hour.</prim_outcome>
      <prim_outcome>Oxigen therapy duration. Timepoint: Time interval from start to end of Oxigen therapy. Method of measurement: Minute and hour.</prim_outcome>
      <prim_outcome>Hospitalization length. Timepoint: Time from hospitalization to discharge. Method of measurement: Day.</prim_outcome>
      <prim_outcome>Time to start feeding based on Silverman Anderson score less than 4. Timepoint: Time to start feeding in day. Method of measurement: Calendar.</prim_outcome>
      <prim_outcome>Stabilization of respiratory rate and heart rate. Timepoint: Calculate the stabilization time of respiratory rate and heart rate. Method of measurement: Hour.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Vice chancellor for research, Mazandaran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-07-12</approval_date>
        <contact_name>Ethics committee of Mazandaran University of Medical Sciences</contact_name>
        <contact_address>Vice chancellor for Research, Moallem square, Sari, Iran Sari Mazandaran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
